Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride
|ClinicalTrials.gov Identifier: NCT00662337|
Recruitment Status : Completed
First Posted : April 21, 2008
Last Update Posted : September 8, 2011
|Condition or disease||Intervention/treatment||Phase|
|Nasal Congestion||Drug: Diphenhydramine hydrochloride||Phase 1|
Subjects were required to observe a ten-hour fast and a one-hour fluid restriction prior to each dosing period.
Subjects were randomized into one of two active treatment groups, received supervised dosing of their treatment with approximately eight ounces of water, and were required to maintain fluid restriction for one hour after treatment. Following the one-hour post-dose fluid restriction, subjects could drink water, but consumer no other food or fluids for four hours post-dose.
Following a seven-day washout period, the comparison treatment was administered according to the same procedure as above.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||A Randomized, Two-Way Crossover Evaluation of the Bioequivalence Between Two Oral Formulations of Diphenhydramine: ULTRATAB Tablet Versus KAPSEALS Capsule|
|Study Start Date :||October 2006|
|Actual Primary Completion Date :||November 2006|
|Actual Study Completion Date :||November 2006|
Drug: Diphenhydramine hydrochloride
After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
- Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUC0-t and AUC0-infinity [ Time Frame: At 15 minutes pre-dose (0 hour), and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 36 and 48 hours post-dose ]
- The safety analysis included all subjects who took at least one dose of clinical trial test product and had any follow-up information. Subjects in the safety analysis set were summarized and listed, based on actual treatment received. [ Time Frame: 15 minutes pre-dose (0 hour) through 28 days post-dose ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00662337
|Study Director:||Melissa Israel, BS||McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|